3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
NIH
3
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Peripheral
6
Hematologic Neoplasms
4
Urinary Bladder Neoplasms
3
Sarcoma
3
Ovarian Neoplasms
3
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Thyroid Neoplasms
2
Parathyroid Neoplasms
2
Otorhinolaryngologic Neoplasms
2
Osteosarcoma
2
Neoplasms
2
Multiple Myeloma
2
Mixed Tumor, Mesodermal
2
Mesothelioma, Cystic
2
Mesothelioma
2
Lymphoma, T-Cell
2
Lymphoma
2
Liposarcoma
2
Leiomyosarcoma
2
Kidney Neoplasms
2
Hemangiosarcoma
2
Head and Neck Neoplasms
2
Fibrosarcoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Chondrosarcoma
2
Carcinoma, Small Cell
2
Breast Neoplasms
2
Adenosarcoma
2
Interventions
mogamulizumab
4
denileukin diftitox
4
Vorinostat
4
Panobinostat
4
zanolimumab
3
cobomarsen
3
Brentuximab Vedotin
3
Bexarotene
3
tenalisib
2
selinexor
2
marizomib
2
hypericin
2
Vitamin B 12
2
Rituximab
2
Folic Acid
2
A-dmDT390-bisFv(UCHT1) protein
2
10-propargyl-10-deazaaminopterin
2
tislelizumab
1
tinostamustine
1
sapacitabine
1
romidepsin
1
resminostat
1
quisinostat
1
ontuxizumab
1
navitoclax
1
forodesine
1
fludarabine phosphate
1
enzastaurin
1
belinostat
1
abexinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, T-Cell, Cutaneous
×
belinostat
×
Clear all
NCT00274651
2015-07-28
PXD101-CLN-6
Valerio Therapeutics
Phase 2
Terminated
53 enrolled
12 charts